Personal care company Nu Skin (NYSE:NUS) will be announcing earnings results tomorrow after market close. Here's what investors should know.
Last quarter Nu Skin reported revenues of $498.8 million, down 7.3% year on year, missing analyst expectations by 4.1%. It was a weak quarter for the company, with underwhelming earnings guidance for the next quarter.
Is Nu Skin buy or sell heading into the earnings? Find out by reading the original article on StockStory.
This quarter analysts are expecting Nu Skin's revenue to decline 8.8% year on year to $476.4 million, improvement on the 22.4% year-over-year decrease in revenue the company had recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.28 per share.
Majority of analysts covering the company have reconfirmed their estimates over the last thirty days, suggesting they are expecting the business to stay the course heading into the earnings. The company missed Wall St's revenue estimates five times over the last two years.
Looking at Nu Skin's peers in the personal care segment, some of them have already reported Q4 earnings results, giving us a hint of what we can expect. e.l.f. delivered top-line growth of 84.9% year on year, beating analyst estimates by 13.4% and Coty (NYSE:COTY) reported revenues up 13.4% year on year, exceeding estimates by 2.9%. e.l.f. traded up 1.7% on the results, and Coty was down 1.6%.
Read the full analysis of e.l.f.'s and Coty's results on StockStory.
Investors in the personal care segment have had steady hands going into the earnings, with the stocks up on average 1.7% over the last month. Nu Skin is up 7.2% during the same time, and is heading into the earnings with analyst price target of $21, compared to share price of $18.9.
